Amgen, newer rivals could threaten Novo Nordisk and Eli Lilly's weight loss drug dominanceCNBC • 05/07/24
Big pharma is looking to fatten profits with buyouts of weight-loss drug companies. Here are 4 candidates.Market Watch • 04/16/24
Structure Therapeutics to Present at Leerink Partners Global Biopharma ConferenceGlobeNewsWire • 03/08/24
Structure Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent HighlightsGlobeNewsWire • 03/08/24
The weight loss drug market may soon get more crowded – here are the companies trying to enter the booming spaceCNBC • 01/17/24
Structure Therapeutics Stock Just Crashed. Here's Why It Could Be Worth Buying NowThe Motley Fool • 12/25/23
Five obesity-drug trends to watch in 2024: Who can compete with Eli Lilly and Novo Nordisk?Market Watch • 12/20/23
Structure Therapeutics shares sink after obesity drug trial results disappointProactive Investors • 12/18/23
Structure Stock Takes A Brutal Beating After Obesity Drug Trails Lilly's LeaderInvestors Business Daily • 12/18/23
Structure Therapeutics Provides Comprehensive GSBR-1290 Program Update Including Clinically Meaningful Proof-of-Concept Data From Phase 2a Clinical StudyGlobeNewsWire • 12/18/23
If You Can Only Buy One Biotech Stock in December, It Better Be One of These 3 NamesInvestorPlace • 11/29/23
Structure Therapeutics Reports Third Quarter 2023 Financial Results and Recent HighlightsGlobeNewsWire • 11/14/23